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Background: Foeniculum vulgare locally known as ensilal, is an aromatic plant widely cultivated in temperate and
tropical regions. The anti-anxiety activity of the crude extract of F. vulgare has been reported. However, the fraction
responsible for anxiolytic activity is not known and there is no any report on the anti-anxiety activity of the essential oil
of F. vulgare. The objective of study was to evaluate the anxiolytic activity of the essential oil of Foeniculum vulgare Miller.
Methods: Adult Swiss albino male mice were randomly divided into six groups (n = 6). Groups I and II received
Tween 80 (5%, v/v) and diazepam (0.5 mg/kg, ip), respectively, while groups III to V received orally 50, 100, and 200 and
400 mg/kg doses of the essential oil of F. vulgare, respectively. The mice were then individually placed in animal anxiety
models: elevated plus maze (EPM), staircase test (SCT) and open field test (OFT) and evaluated for various parameters.
Results: In EPM test, 100 and 200 mg/kg doses of the essential oil significantly increased percent number of entries
and time spent in open arms compared to control. In SCT these doses also reduced rearing significantly compared
to controls, while only the 200 mg/kg dose significantly increased number of squares crossed at the center in the
OFT test.
Conclusion: The essential oil of F. vulgare was found to exhibit a promising anxiolytic activity.
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Anxiety disorders are among the most common mental,
emotional, and behavioral problems affecting one-eighth
of the total population worldwide, and have become a
very important area of research interest in psycho-
pharmacology. Anxiety represents a heterogenous group
of disorders, probably with no single unifying etiology;
various psychodynamic, psychoanalytic, behavioral, cogni-
tive, genetic and biological theories have been proposed to
explain the etiology of anxiety disorders [1]. It is reported
to have increasing prevalence in recent cohorts in many
countries and to have much earlier ages of onset than
other commonly occurring chronic conditions [2]. Anxiety
disorders cause performance impairments on numerous
tasks and are associated with high rates of medically* Correspondence: workineh.shibeshi@aau.edu.et
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unless otherwise stated.unexplained symptoms, increased utilization of healthcare,
strongly and independently associated with chronic medical
illnesses, low levels of quality of life and disability [3,4].
Pharmacologic treatment of anxiety through the ages has
included different drugs. The first class of drugs developed
(barbiturates) was highly effective, unfortunately, the barbi-
turates can cause respiratory arrest and have a narrow
therapeutic index [5]. The benzodiazepines were developed
as a safer alternative to barbiturates, however, their benefi-
cial effects are overshadowed by the emergence of physical
and psychological dependence and withdrawal reactions
[6,7]. Other drugs used for treatment of anxiety having
unfavorable side-effect profiles include buspirone [8,9],
antidepressants [10-12] and beta-blockers [5].
Due to adverse effects associated with the currently
available drugs, patients on anxiolytic drugs usually
terminate the treatment before full recovery [13]. In
addition, one-third of patients in controlled studies areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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there is a critical need for development of newer anxiolytic
agents. In the search for new therapeutic products for
the treatment of neurological disorders, medicinal plant
research, worldwide, has progressed constantly, demon-
strating the pharmacological effectiveness of different
plant species in a variety of animal models [15]. Several
essential oils obtained from plants are employed in order
to balance emotions, improve physical and mental well-
being [16]. Foeniculum vulgare Mill. locally known as
ensilal or commonly known as fennel, is an aromatic plant
widely cultivated in temperate and tropical regions [17].
The chemical constituents of F. vulgare include essential
oil, fatty acid, phenylpropanoids, monoter-penids, sesqui-
terpenes and coumarins. It also contains triterpenoids,
tannins, flavonoids, cardiac glycosides, saponins, and other
types of compounds [18,19].
The essential oil of F. vulgare is characterized by the
presence of several components including major compo-
nents trans-anethole, fenchone, methyl chavicol, eugnol,
limonene, p-anisaldehyde, α-phellandrene, α-pinene, 1,8-
cineole, γ-terpinene and P-cymene. Compounds such as
3-methylbutanol, linalool, β-pinene, mycerene, δ-3-carene,
camphor, α-terpinol, cis-anethole, thymol are also found
in lower concentration [20]. The essential oil of F. vulgare
is generally recognized safe as the toxicity it may cause is
negligible [21].
In traditional medicine, F. vulgare is used to: encourage
menstruation and lactation, stimulate gastrointestinal
motility, relieve intestinal gas accumulation, improve
eyesight, alleviate productive coughs, ease spasm, pro-
mote courage and mental strength, reduce stress and
nervousness and produce calming [22,23]. The medicinal
properties of F. vulgare as evidenced by different animal
and clinical studies include, antibacterial and antifungal
[24], antioxidant [25], anti-inflammatory [26], anti-athero-
sclerotic [27], gastroprotective [28], hepatoprotective [29],
and diuretic [30]. The anti-anxiety activity of the crude
extract of F. vulgare has been reported [31,32]. However,
the fraction responsible for anxiolytic activity is not known
and there is no any report on the anti-anxiety activity of
the essential oil of F. vulgare.
Thus, the objective of this study was to evaluate the
anxiolytic activities of essential oil of F. vulgare in animal
models of anxiety.Methods
Chemicals
The chemicals used in the experiment include diazepam
(Intlas Pharmaceuticals, India), tween 80 (Research-lab fine
Chem Industries, India), anhydrous sodium sulfate (Bio-lab
laboratories Ltd, Israel) and ethyl alcohol (Changshu
Yangyuan Chemical, China).Plant material
The fresh aerial parts of F. vulgare were purchased from
local market in Addis Ababa. The plant was identified at
the National Herbarium, College of Natural Sciences,
Addis Ababa University, where a voucher specimen was
deposited (collection number MM001).
Experimental animals
Adult Swiss albino male mice weighting 25-35 g were
obtained from rodent breeding unit of the School of
Pharmacy, Addis Ababa University. The animals were
housed under standard environmental conditions and were
allowed free access to tap water and standard laboratory
pellet ad libitum. The ethical handling (33) of mice used
in our study and the experimental protocols used were
approved by Research and Ethics committee of the School
of Pharmacy, Addis Ababa University.
Extraction of essential oil
About 3 Kg of the fresh leaves of F. vulgare were dis-
tilled by hydrodistillation for a period of about 3 h using
Clevenger-type apparatus. The oil was dried over anhyd-
rous sodium sulphate to remove traces of moisture and
stored in a vial inside a refrigerator at 4°C until use.
Acute toxicity study
Acute oral toxicity study was determined by using five
female mice weighing 25–30 g. The mice were fasted for
3 h prior to the experiment. The mice were administered
using oral gavage a single high dose (2000 mg/kg) of the
essential oil and were observed for any symptoms of tox-
icity continuously for 1 h, intermittently for 4 h, over a
period of 24 h and for 14 days [33].
Experimental designs
The mice were randomly divided into six groups (n = 6).
The first group received the vehicle (5% Tween 80 in
distilled water), the second group received standard
drug, diazepam (0.5 mg/kg, Ip). Groups III to VI using
oral gavage received 50, 100, 200 and 400 mg/kg doses
of the essential oil, respectively. The doses were selected
based on the results of the oral acute toxicity study.
Taking into account the safety of the essential oil, 1/
10th of the maximum dose (2000 mg/kg) given in the
toxicity study limit test was considered as a middle dose
(200 mg/kg). Double, one-fourth and half of the middle
dose were assigned as high dose (400 mg/kg), first low
dose (50 mg/kg) and second low dose (100 mg/kg)
respectively.
After 30 min of diazepam treatment or 60 min essential
oil/vehicle pretreatment, the mice were individually placed
in animal models. All the tests were carried out at night
with a minimal amount of background noise. After each
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any olfactory cues to the next animal [34].Elevated plus maze (EPM)
The test was conducted using apparatus validated by
Lister [35]. After each mouse was placed in the centre of
the maze facing one of the open arms, the number of
entries made into the open and closed arms and the
time spent in them was recorded, using a video camera
for the next five min. From these data, the percentage of
entries and the percentage of time spent in each arms
was calculated.Staircase test (SCT)
SCT was carried out as used by Simiand et al. [36]. Each
mouse was placed on the floor of the box with its back
to the staircase, then the number of steps climbed and the
numbers of rears were recorded over 3 min period using a
video camera placed over head. A step is considered to be
climbed only if the mouse had placed all four paws on
the step, the number of steps descended was not taken
into account.Open field test (OFT)
The test was conducted as described by Aragao et al.
[37]. Briefly, the mice were placed individually in a cor-
ner square of the OFT apparatus and the total number
of squares crossed at the periphery, number of central
squares crossed, total number of squares traveled, and
the time the mouse spent in the center were video
recorded for 5 min.Statistical analysis
The data are presented as mean ± S.E.M (standard error
of mean) of six mice. Statistical analysis of the data was
performed using one-way analysis of variance (ANOVA)
followed by Tukey posthoc test. Significant differences
were set at P values lower than 0.05.Table 1 The behavior of mice treated with the essential oil of
elevated plus maze model
Treatment Dose,
mg/kg
Number of entries (counts/5 min)
Open arm Closed arm Total
Vehicle - 3.17 ± 1.33 8.50 ± 2.59 11.67 ±
FV 50 4.83 ± 1.72 6.83 ± 0.75 11.66 ±
FV 100 7.50 ± 4.59 5.83 ± 3.31 13.66 ±
FV 200 11.00 ± 5.48a* 8.00 ± 4.90 19.00 ±
FV 400 4.01 ± 2.10 4.00 ± 1.4 a* 8.00 ±
Diazepam 0.5 10.83 ± 9.06a* 6.50 ± 2.59 17.50 ±
Data are presented as mean ± S.E.M, n = 6, *P < 0.05, **P < 0.01, aagainst control, bag
vulgare essential oil.Results
Acute toxicity test
After the administration of 2000 mg/Kg dose of the
essential oil of F. vulgare, the animals didn’t show loss of
weight, autonomic behavioral changes or other signs of
toxicity. There was also no mortality observed in the
study period, suggesting that the LD50 (median lethal
oral dose) of the essential oil is higher than 2000 mg/kg
when given orally [33].
Anxiolytic effects
In the EPM paradigm (Table 1), the essential oil at
200 mg/kg dose showed significant increase in the number
of entries into the open arms compared to the negative
control, while all other doses of the oil did not significantly
affect the parameter compared. On the other hand, none of
the doses of the oil or diazepam significantly affected the
number of closed arm entries except the 400 mg/kg dose
which significantly decreased the parameter. The time the
mice spent in the open arms was significantly increased in
animals treated with 100 and 200 mg/kg doses of the oil
compared to the control group. Mice treated with 100 and
200 mg/kg doses significantly increased the percentage of
open arm entry compared to the vehicle (Figure 1) and at
a dose of 200 mg/kg the oil produced a significant reduc-
tion in the percentage of time spent in the closed arms
(Figure 2).
In SCT (Table 2), mice treated with the 100 and
200 mg/kg doses of the oil showed significant reduction
of rearing compared to control group, however, only
200 mg/kg dose of the oil showed statistically significant
reduction in rearing compared with diazepam. The reduc-
tion in the number of climbing was produced by the
essential oil only at 400 mg/kg dose compared with
control, while other doses were not effective.
In the OFT model, the number of central squares crossed
was increased in all groups treated with the essential
oil, however, statistical significance was reached only in
the groups treated with 200 mg/kg compared to the
control (Table 3). In mice treated with 400 mg/kg theFoeniculum vulgare and reference compounds in the
Time spent (sec/5 min)
Open arm Closed arm Center
3.66 44.17 ± 20.19 137.83 ± 38.24 118.00 ± 41.25
1.37 68.00 ± 25.69 117.50 ± 46.78 114.50 ± 50.03
3.78 109.67 ± 48.64a* 99.83 ± 43.32 90.50 ± 33.59
9.87c* 112.67 ± 35.62a* 71.33 ± 37.17a* 119.00 ± 36.87
2.76(b, d)* 87.50 ± 36.32 93.33 ± 35.27 119.17 ± 27.13
8.53 c* 123.67 ± 50.67a** 67.33 ± 34.63a* 84.67 ± 44.23
ainst 200 mg/kg, cagainst 400 mg/kg, dagainst diazepam; FV = Foeniculum
Figure 1 Effects of the essential oil of Foeniculum vulgare and controls on percentage of arm entries in the elevated plus maze (EPM)
test in mice. Data are mean ± S.E.M (n = 6); *P < 0.05, **P < 0.01, compared with vehicle. FV = Foeniculum vulgare essential oil.
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crossed at the periphery compared to both vehicle and
200 mg/kg dose was noted. Mice treated with 100 and
200 mg/kg dose of the essential oil spent more time in
the central squares compared to the control group.
Discussion
The present work has evaluated the anxiolytic activity of
various doses of the essential oil of F. vulgare in mice
employing three non-conditioned behavioral animal models
of anxiety; EPM model, OFT and SCT. These tests are
classic and standard models for screening central nervous
system actions providing information about anxiety and
psychomotor performance [38]. Further, these models can
create an anxiety state in normal rodents in a reproducible
paradigm while minimizing some of the confounding
factors of other conditioned assays [39].
The EPM test is principally based on the behavior that
exposure of animals to an elevated maze alley evokes anFigure 2 Effects of the essential oil of Foeniculum vulgare and controls
test in mice. Data are expressed as mean ± S.E.M. (n = 6); *P < 0.05, **P < 0.01approach-avoidance conflict and rodents consistently
spend greater time in the closed arms when placed in
mazes comprising of open and closed arms [40]. Based
on these assertions, EPM tests are reliable means of
identifying selective anxiolytic effect of drugs and used
as a tool in the investigation of the psychological and
neuro-chemical basis of anxiety, for screening anxiety-
modulating drugs or mouse genotypes [41]. The EPM
test has been validated pharmacologically, physiologically
and behaviorally, and has become one of the most
widely used behavioral tests for anxiety [34]. Anxiety is
induced by a fear due to height in rodents when placed
on the EPM. The ultimate manifestation of anxiety is
exhibited by preference to remain at safer places and a
decrease in the motor activity.
Treatment of mice with the essential oil of F. vulgare
resulted in significant alterations on the behavioral
responses measured in the EPM test. Experimental
animals treated with 100 and 200 mg/kg doses of F.on the percentage of duration in arms in the elevated plus maze
as compared to control. FV = Foeniculum vulgare essential oil.
Table 2 Effect produced by administration of the
essential oil of Foeniculum vulgare and reference
compounds to mice in the staircase test
Treatment Dose (mg/kg) Number of rearing Number of
stairs climbed
Vehicle - 19.67 ± 2.50 16.17 ± 6.11
FV 50 15.00 ± 1.67 d** 18.00 ± 4.19 e**
FV 100 13.33 ± 4.93a* d* 13.34 ± 1.37
FV 200 8.00 ± 3.03 (a, b, e)**. (c, f)* 11.50 ± 3.56
FV 400 18.33 ± 3.44 d** 9.50 ± 4.09 a*. b**
Diazepam 0.5 14.00 ± 3.29(a*.d*) 12.00 ± 4.56
Data are mean ± S.E.M, n = 6, acompared with vehicle, bto 50 mg/kg, cto
100 mg/kg, dto 200 mg/kg, eto 400 mg/kg, fto diazepam, *P < 0.05, **P < 0.01.
FV = Foeniculum vulgare essential oil.
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percentage of number of entries into the open arms.
This decreased aversion to open arms compared to
control group indicated its anxiolytic activity [40]. The
decrease in aversion to open arms by the 100 and
200 mg/kg doses of the oil was also verified by the
increased percentage of time spent in the open arms
compared with the negative control.
Time spent in the central platform of EPM appears to
be related to decision making and/or risk assessment.
A decreased time spent on the central platform serves
as indicator of a reduced decision making behavior, a
parameter accepted as reliable indicators of anxiety and
fearfulness [42]. However, neither doses of the essential
oil nor diazepam altered the parameter significantly
compared to control. At a dose of 400 mg/kg, however,
the oil showed a significant decrease on the number of
entries in the closed arms. The absence of significant
modification in the number of closed arm entries, in
the anxiolytic doses of the oil, in the EPM indicated
that the anxiolytic activity was observed at doses that
did not impair motor activity [43].
The EPM test is one of the most popular tests for
search of new benzodiazepine-like anxiolytic agents [44].
In this context, the activity of the essential oil of F.Table 3 Effect of the essential oil of Foeniculum vulgare and r
field model




Vehicle 2.17 ± 1.33 2.00 ± 1.26
FV50 3.33 ± 5.92 c* 3.67 ± 7.12 d*
FV100 10.67 ± 4.32 (a, b)* 9.00 ± 7.54
FV200 10.50 ± 4.04 a* 14.50 ± 3.27 (a,b,e
FV400 4.50 ± 5.92 3.34 ± 4.55 d*
Diazepam 9.33 ± 5.32 a* 12.83 ± 10.66 a*
The data are mean ± S.E.M, n = 6, aagainst control, bagainst 50 mg/kg, cagainst 100
and **P < 0.01. FV = Foeniculum vulgare essential oil.vulgare (100 and 200 mg/kg) in relieving anxiety in this
model may suggest a possible positive modulation of
the GABA-A/benzodiazepine receptor complex.
The SCT for screening anxiolytic activity is a simple and
rapid procedure for preliminary screening of anxiolytic
agents [45]. Step climbing reflects exploratory or locomotor
activity, while rearing behavior was a manifestation of
anxiety state [46]. The present study showed that exposure
of the experimental animals to the essential oil of F. vulgare
significantly reduced rearing activity at doses (100 and
200 mg/kg) that did not suppress climbing, aligning with
a behavior of an anxiolytic compound in a staircase model
[47]. At a dose of 400 mg/kg, the essential oil produced
a significant reduction in the number of steps ascended
indicating suppression of locomotor activity, which is
interpreted as a sedative, rather than anxiolytic effect in
different studies [46,48]. Only GABA receptor complex
active agents have been shown to reduce rearing at
doses that do not reduce climbing in the SCT. Other
non-benzodiazepine compounds induce non-specific sup-
pression of both rearing and climbing behavior [49],
strengthening the suggested possible mechanism of the oil.
The OFT is a classical animal model used to evaluate
effects of drugs on anxiety, general motor activity and
exploratory behavior. It uses the normal aversion of rodents
to an open, brightly lit area, as the confrontation with the
situation induces anxiety behavior in rodents [50]. Rodents
normally spend more time in the protective corners,
suggesting that the walls confer anxiety-relieving body
contact. When animals are placed in OFT, they express
their anxiety by a decrease in exploratory behavior [51].
Increased entry and the time spent in the center of the
arena in the OFT reflects decreased anxiety altered by
anxiolytic property, as measures of central exploration are
often regarded as anxiety-related indices [52]. Diazepam
significantly increased the total number of squares traveled
at the periphery, which may be an increase in exploratory
activity on reduced anxiety. The anxiolytic activity of the
essential oil at the effective doses (100 and 200 mg/kg),
could not be confirmed by this parameter, as the increaseeference compounds on the behavior of mice in the open
Number of squared crossed
Periphery Total
85.17 ± 19.37 87.16 ± 19.31
80.83 ± 25.34 84.50 ± 25.99
79.33 ± 10.32 f** 88.33 ± 17.81 f**
)* 87.50 ± 19.67 (e, f)* 102.00 ± 21.87 e*
53.00 ± 4.94 (a ,d)* 56.33 ± 7.76 d*
122.67 ± 31.6(a, d)*.c** 133.83 ± 34.93(a, c)**
mg/kg, dagainst 200 mg/kg, eagainst 400 mg/kg, fagainst diazepam, *P < 0.05
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effect [53]. The decrease in ambulation at the highest
dose (400 mg/kg) of the oil might be due to the sedative
property of the oil. Suppression of exploratory behavior is
an indication of central nervous system depressant activity
[44]. This decline in activity at highest doses of the essen-
tial oil in EPM, SCT and OFT can be correlated well with
each other.
In the present study, the activity of F. vulgare corre-
sponding to the doses given had seemingly a biphasic
inverted-U (bell) shape, as the administration of the
highest (400 mg/kg) and lowest (50 mg/kg) doses showed
insignificant low effects whereas the 100 mg/kg and
200 mg/kg dose levels produced significant effects and
the peak in mean response was shown at 200 mg/kg.
The ineffectiveness of the lowest dose of the oil may be
because it is a sub-threshold level. However, the lack of
effect at the highest dose level may be due to a decreased
locomotion which might be due to an interference with
a normal sensory-motor function or sedative effect. The
sedative activity of the essential oil is also verified by a
research [54]. Such inverted U-shaped functions are also
typical of conventional anxiolytics (benzodiazepines and
buspirone) that, in addition to reducing anxiety, also
impair motor performance at high doses [55].
The effects of F. vulgare essential oil in the anxiety
models were comparable or better in some cases to those
of the standard anxiolytic drug diazepam at the doses
used. Overall, the results indicated that the essential oil of
F. vulgare can be further studied for optimum dosage to
be used as a future of anti-anxiety drug development or as
a standardized Phytomedicine.
The major component of the essential oil, anethole,
which is the methyl ether of estrone, has been reported to
display a potent estrogenic activity [56]. There is a correl-
ation between decreased estrogen levels and increased
anxiety [57,58]. Further, anethole has a structural similar-
ity with dopamine [59]. In other studies [60,61], the minor
components of the essential oil of F. vulgare including
(+)-limonene, linalool, pinene and eugenol have also been
reported to have anxiety relieving like activities.Conclusion
The lower doses of the essential oil of the aerial parts of
F. vulgare possess anxiolytic activity, while at a higher
dose the oil appears to be potentially sedative. Thus, the
results of the present study indicate that the essential oil
of F. vulgare may have potential clinical applications in
the management of anxiety.Abbreviations
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